CA-ARIBIO-CO.,-LTD.
31.3.2023 18:01:37 CEST | Business Wire | Press release
AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins.
The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States.
Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatment in a post-hoc analysis, including a dose dependent decline of pTau181 at 26 weeks, and further declines after 52 weeks of treatment. Patients randomized to 10 and 30 mg AR1001 treatment after 26 weeks of treatment with placebo also demonstrated similar declines in pTau181. Other plasma markers including NfL, GFAP and AB42/40 ratio were also measured but showed minimal change or no statistical differences over baseline levels.
AriBio initiated a phase 3 pivotal trial with 30mg of AR1001 to be administered daily to early and mild Alzheimer’s disease patients in December of 2022. Enrollment is expected to continue through 2024. “This biomarker data helps bolster the positive effects seen in cognition with the high dose of AR1001 in the Phase 2 study in mild AD patients. We will continue to collect both CSF and plasma as part of the phase 3 study to analyze as supportive data,” stated Dr. Greeley.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is a Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005009/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Saudi Fund for Development Signs USD 15 Million Agreement with the Republic of Palau to Drive Local Economic Growth6.4.2026 21:01:00 CEST | Press release
The Saudi Fund for Development (SFD) today signed a USD 15 million development loan agreement with the Republic of Palau, marking the Fund’s first-ever development partnership in the Pacific island nation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260406306007/en/ Saudi Fund for Development Signs USD 15 Million Agreement with the Republic of Palau to Drive Local Economic Growth (Photo: AETOSWire) The agreement was signed by H.E. Sultan Abdulrahman Al-Marshad, Chief Executive Officer of SFD, and H.E. Surangel S. Whipps Jr., President of the Republic of Palau during a ceremony in Palau’s capital, Ngerulmud. The USD 15 million development loan will be channeled through the National Development Bank of Palau. Designed to empower the local economy, the financing will support projects spearheaded by Palauan developers, businesses, and entrepreneurs. By aligning with Palau’s national priorities, the funds will catalyze high-im
Bureau Veritas Acquires Lotusworks, Reinforcing Its Position in Data Centers and Entering the Semiconductor Sector; This Establishes a New c.Eur 300 Million Growth Platform6.4.2026 20:00:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces that it has signed an agreement to acquire Lotusworks, a global leader in mission‑critical assets commissioning and quality assurance and control. This strategic move will uniquely position the Buildings & Infrastructure Product Line to benefit from AI-driven construction investments. Headquartered in Ireland, Lotusworks is a leading provider of commissioning, quality assurance and quality control, calibration, maintenance, and construction management services for mission‑critical facilities for semiconductors manufacturers and data center owners. The Company operates in the United States and Europe, and employs 750 people including highly skilled experts, serving a diversified base of blue‑chip global clients, including hyperscalers and semiconductor manufacturers. Lotusworks’ activity is supported by long‑term frameworks, a strong multi‑year backlog, and recurring technical services in
Svante & Meadow Lake Tribal Council Partnership Agrees to Sell Microsoft 626,000 Tonnes of Carbon Removal Credits6.4.2026 17:00:00 CEST | Press release
Microsoft agrees to purchase 626,000 tonnes of durable carbon dioxide removal (CDR) credits over a 15-year delivery term from the North Star BECCS project in Saskatchewan, Canada. Indigenous ownership: North Star Carbon Solutions LP is a Meadow Lake Tribal Council (MLTC)–Svante partnership. The deal is Microsoft’s first Canadian BECCS CDR offtake agreement and is believed to be the first of its kind in Canada involving Indigenous ownership. The project is co-located at the MLTC Bioenergy Centre and supplied by sustainable waste biomass from MLTC’s adjacent sawmill. Svante Technologies Inc. (Svante) and Meadow Lake Tribal Council (MLTC) announced today that North Star Carbon Solutions LP has entered into an offtake agreement with Microsoft to deliver 626,000 tonnes of durable carbon dioxide removal (CDR) credits to be delivered over 15 years from the North Star bioenergy with carbon capture and storage (BECCS) project in Saskatchewan, Canada. The project is being developed through a par
Textron Aviation Names Five 2026 Top Hawk Recipients as Program Enters Its Second Decade of Workforce Impact6.4.2026 17:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced Brazos Valley Flight Services, Executive Air Taxi Corporation, Fairmont State University, Sterling Flight Training and Victors Aviation as its 2026 Top Hawk program recipients, continuing a legacy that has placed 55 factory-new Cessna Skyhawks in training environments since the program launched in 2015. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402481685/en/ Factory-new Cessna Skyhawks (Model 172) to take flight as Textron Aviation names five 2026 Top Hawk recipients—helping train the next generation of pilots Now entering its second decade, Top Hawk is one of the industry’s longest‑running manufacturer‑school partnerships. Designed to support aviation workforce development, the program loans custom‑branded, factory‑new Skyhawks to selected organizations for one year, giving students access to the world’s most popular training aircraft and help
The Spectrum of Global Cinema Unfolds in Jeonju: The 27th JEONJU International Film Festival6.4.2026 15:23:00 CEST | Press release
237 films from 54 countries to be screened under the slogan “Beyond the Frame” The 27th JEONJU International Film Festival (JIFF) is set to run from April 29 to May 8 in Jeonju, featuring 237 movies from 54 countries. Jeonju—the most authentic Korean city and a prominent tourist destination in Asia known for its tradition and cuisine—will host this year’s film festival under the slogan “Beyond the Frame.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260406890043/en/ The 27th JEONJU International Film Festival will take place from April 29 to May 8 in Jeonju (Image: JEONJU CITY) Opening the 27th edition will be Kent Jones’s “Late Fame,” while the film “The Longest Night: Namtaeryong” directed by Kim Hyun-ji will close the festival. In addition, a special program honors the late Korean actor Ahn Sung-ki, who passed away last year. Titled “Special Focus: Ahn Sung-ki’s Memorable Films Yet Rarely Seen,” it showcases seven of hi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom